
More Than Skin Deep: A New Partnership to Ease the Hidden Burden of Eczema in the UAE
Together, Jamjoom Pharma and EDS hope to drive a cultural shift in how chronic skin conditions are perceived and managed, transforming frustration into understanding—and silence into support.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Travis Kelce in Disbelief That Taylor Swift Picked Him, Says ‘Source'
Travis Kelce and Taylor Swift have never failed to swoon their fans with their love for each other. According to a source, the NFL player is still in disbelief that the singer has picked him as her partner. Recently, he made it evident when an onlooker stated that he has 'the best girlfriend,' with the Kansas City Chiefs tight end agreeing while blushing. The power couple has been dating since 2023 and has not shied away from flaunting their PDA-filled moments to the world. Travis Kelce and Taylor Swift have been gaining attention because of their public appearances for quite some time now. Even when they are not together, people love bringing up their partners. In one such incident, the Kansas City Chiefs tight end became the center of attention at the American Century Championship in Nevada. A video shared on X (formerly Twitter) showed Kelce golfing, surrounded by a group. An individual who was recording the clip exclaimed, 'You have the best girlfriend in the world!' The NFL star seemingly blushed and responded, 'Good point,' making the crowd laugh. Referring to this occurrence, a source close to the couple told Rob Shuter, 'He still acts like he can't believe she picked him. And she loves that.' Last month, the couple made heads turn with their first red carpet appearance at the Tight End University (TEU) summit in Nashville. Swift accompanied her boyfriend and had a blast with his acquaintances. She surprised the people present at the event with a concert alongside Kane Brown and also danced intimately with her beau. Their dance videos to the pop star's hit songs at the Nashville event went viral online. Kelce opened up about his girlfriend and their time at the summit during an episode of the 'New Heights' podcast. The footballer gushed about his girlfriend and stated, 'She's so good with everybody,' and that she 'absolutely rocked the stage yet again. It was awesome.' The post Travis Kelce in Disbelief That Taylor Swift Picked Him, Says 'Source' appeared first on Reality Tea.
Yahoo
27 minutes ago
- Yahoo
Cholera outbreak strains health system at a mining camp in Congo
STORY: :: Lomera, DRC :: June 18, 2025 A cholera outbreak has infected more than 600 people at an artisanal gold mine in South Kivu province, overwhelming local health services and exposing severe sanitation challenges in the conflict-hit eastern Congo. Many patients, like Riziki Bachoke, described severe symptoms and were treated at this makeshift center run by Médecins Sans Frontières (MSF). "I have been here for two days, suffering from diarrhea. I was brought here in a critical condition. I also had dizziness, but when I arrived here, they examined me before giving me medication. I took syrups and serum. After three days, I feel good. I am strong and I say thank you very much." Cholera is a bacterial infection caused by consuming contaminated water or food. It can kill within hours if untreated. Aid workers and health officials warn of recurring outbreaks without proper sanitation infrastructure, clean water, and long-term healthcare investment. Earlier this year, North Kivu recorded over 600 suspected cholera cases and 14 deaths in one month, raising concerns about similar trends in South Kivu's informal settlements like Lomera. :: Katana, DRC :: July 2, 2025 Dr. Justin Bengehya of the South Kivu Provincial Health Division reported 5,360 cases and 28 deaths across the province since early 2025. The epidemic has raged in Lomera for nearly two months, he says, and most of those affected are miners and small traders. The World Health Organization (WHO) has flagged rising infectious disease risks in eastern Congo amid ongoing displacement and violence.
Yahoo
27 minutes ago
- Yahoo
How Will Pfizer's Oncology Drugs Perform in Q2 Earnings?
Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, Tukysa and Tivdak — to the company's portfolio. In first-quarter 2025, oncology contributed more than 25% to Pfizer's total revenues, growing 7% year over year. Investors will be closely watching this segment when Pfizer reports second-quarter results on Aug. 5. Within the oncology unit, sales of Xtandi, Lorbrena and Braftovi/Mektovi are likely to have increased during the quarter. However, sales of key medicine Ibrance are expected to have been hurt due to continued competitive pressure across markets, generic entry and the Inflation Reduction Act ("IRA") impact in the United States. With regard to ADC products, competitive pressure in the United States is likely to have hurt sales of Adcetris, while strong demand trends must have benefited Padcev's sales. Our model estimates for second-quarter 2025 sales of the overall oncology segment are pegged at $4.0 billion, implying a 2% rise year over year. Beyond oncology, Pfizer's top line is likely to have been aided by its key in-line products like Vyndaqel and Eliquis, alongside newer additions like Nurtec. However, this growth is expected to have been offset by the U.S. Medicare Part D headwinds and the continued declining sales of its COVID-19 products. Other large players in the oncology space are AstraZeneca AZN and Merck MRK. For AstraZeneca, oncology sales now account for nearly 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Merck's key oncology medicines are PD-L1 inhibitor, Keytruda and PARP inhibitor, Lynparza, which it markets in partnership with AstraZeneca. Keytruda, approved for several types of cancer, alone accounted for more than 46% of Merck's total revenues in the first quarter of 2025. Shares of Pfizer have underperformed the industry year to date, as shown in the chart below. Image Source: Zacks Investment Research From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company's shares currently trade at 8.25 times forward earnings, lower than 15.12 for the industry and the stock's 5-year mean of 10.86. Image Source: Zacks Investment Research The bottom-line estimate for 2025 has declined from $3.08 to $3.05, while that for 2026 has gone up from $3.08 to $3.09 over the past 60 days. Image Source: Zacks Investment Research Pfizer currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research